Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246299175> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W4246299175 endingPage "911" @default.
- W4246299175 startingPage "904" @default.
- W4246299175 abstract "PURPOSE The advantage of chemotherapy in asymptomatic patients with advanced colorectal cancer is debatable. Whether early chemotherapy improves survival and the length of the symptom-free period versus no therapy until symptoms appear was studied in a randomized trial. PATIENTS AND METHODS A total of 183 patients with advanced, but asymptomatic colorectal cancer were randomly allocated to receive either initial treatment with sequential methotrexate 250 mg/m2 during the first 2 hours, and fluorouracil (5-FU) 500 mg/m2 at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (MFL) for 12 courses or to primary expectancy with chemotherapy not considered until symptoms appeared. One patient was ineligible and excluded from analysis. Nine patients did not fulfill the inclusion criteria and five patients refused treatment allocation; these patients were not excluded from the study population so as not to introduce bias. So far, 51 of 90 (60%) patients in the expectancy group have received chemotherapy. RESULTS Overall survival was better in the MFL group than in the expectancy group (Breslow-Gehan, P less than .02; log-rank, P = .13) with a difference in median survival of approximately 5 months. Also the symptom-free period and the time to disease progression were longer in the MFL group (P less than .001), with median differences of 8 and 4 months, respectively. Toxicity to MFL treatment was low; however, three patients died because of toxicity--none of them should have received therapy because of poor performance or S-creatinine elevation. The patients maintained an excellent performance throughout the MFL treatment unless the disease was progressive. CONCLUSION We concluded that early treatment with MFL in asymptomatic patients with advanced colorectal cancer prolongs survival, the asymptomatic period, and the time to disease progression by approximately 6 months over primary expectancy." @default.
- W4246299175 created "2022-05-12" @default.
- W4246299175 date "1992-06-01" @default.
- W4246299175 modified "2023-09-30" @default.
- W4246299175 title "Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial." @default.
- W4246299175 doi "https://doi.org/10.1200/jco.1992.10.6.904" @default.
- W4246299175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1588370" @default.
- W4246299175 hasPublicationYear "1992" @default.
- W4246299175 type Work @default.
- W4246299175 citedByCount "275" @default.
- W4246299175 countsByYear W42462991752012 @default.
- W4246299175 countsByYear W42462991752013 @default.
- W4246299175 countsByYear W42462991752014 @default.
- W4246299175 countsByYear W42462991752015 @default.
- W4246299175 countsByYear W42462991752016 @default.
- W4246299175 countsByYear W42462991752017 @default.
- W4246299175 countsByYear W42462991752018 @default.
- W4246299175 countsByYear W42462991752019 @default.
- W4246299175 countsByYear W42462991752020 @default.
- W4246299175 countsByYear W42462991752021 @default.
- W4246299175 countsByYear W42462991752022 @default.
- W4246299175 countsByYear W42462991752023 @default.
- W4246299175 crossrefType "journal-article" @default.
- W4246299175 hasConcept C121608353 @default.
- W4246299175 hasConcept C126322002 @default.
- W4246299175 hasConcept C141071460 @default.
- W4246299175 hasConcept C168563851 @default.
- W4246299175 hasConcept C2776694085 @default.
- W4246299175 hasConcept C2777910003 @default.
- W4246299175 hasConcept C2908647359 @default.
- W4246299175 hasConcept C526805850 @default.
- W4246299175 hasConcept C71924100 @default.
- W4246299175 hasConcept C99454951 @default.
- W4246299175 hasConceptScore W4246299175C121608353 @default.
- W4246299175 hasConceptScore W4246299175C126322002 @default.
- W4246299175 hasConceptScore W4246299175C141071460 @default.
- W4246299175 hasConceptScore W4246299175C168563851 @default.
- W4246299175 hasConceptScore W4246299175C2776694085 @default.
- W4246299175 hasConceptScore W4246299175C2777910003 @default.
- W4246299175 hasConceptScore W4246299175C2908647359 @default.
- W4246299175 hasConceptScore W4246299175C526805850 @default.
- W4246299175 hasConceptScore W4246299175C71924100 @default.
- W4246299175 hasConceptScore W4246299175C99454951 @default.
- W4246299175 hasIssue "6" @default.
- W4246299175 hasLocation W42462991751 @default.
- W4246299175 hasLocation W42462991752 @default.
- W4246299175 hasOpenAccess W4246299175 @default.
- W4246299175 hasPrimaryLocation W42462991751 @default.
- W4246299175 hasRelatedWork W129423339 @default.
- W4246299175 hasRelatedWork W1987215768 @default.
- W4246299175 hasRelatedWork W1991129960 @default.
- W4246299175 hasRelatedWork W1995188757 @default.
- W4246299175 hasRelatedWork W2016679923 @default.
- W4246299175 hasRelatedWork W2116001782 @default.
- W4246299175 hasRelatedWork W2131457795 @default.
- W4246299175 hasRelatedWork W2943195325 @default.
- W4246299175 hasRelatedWork W4229900919 @default.
- W4246299175 hasRelatedWork W17604275 @default.
- W4246299175 hasVolume "10" @default.
- W4246299175 isParatext "false" @default.
- W4246299175 isRetracted "false" @default.
- W4246299175 workType "article" @default.